<DOC>
	<DOCNO>NCT01051401</DOCNO>
	<brief_summary>This randomize pilot clinical trial study rosuvastatin treat woman cardiovascular complication undergo chemotherapy breast cancer . Rosuvastatin may prevent lessen cardiovascular complication patient undergo chemotherapy breast cancer</brief_summary>
	<brief_title>Rosuvastatin Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate feasibility administer Rosuvastatin breast cancer patient undergo treatment anthracyclines , paclitaxel , cyclophosphamide , trastuzumab breast cancer . OUTLINE : Patients randomize 1 2 treatment arm . Arm I : Patients receive rosuvastatin orally ( PO ) daily 3 month absence disease progression unacceptable toxicity . Arm II : Patients receive placebo PO daily 3 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Women receive therapy breast cancer without history cardiovascular disease An lowdensity lipoprotein ( LDL ) cholesterol level le 160 mg per deciliter ( 3.4 MMol per liter ) Willingness participate duration trial ( 3 month ) Written informed consent Triglyceride level le 500 mg per deciliter ( 5.6 mmol per liter ) Previous current use lipidlowering therapy Current use postmenopausal hormonereplacement therapy Evidence hepatic dysfunction ( alanine aminotransferase level twice upper limit normal range ) Creatine kinase level three time upper limit normal range Creatinine level high 2.0 mg per deciliter ( 176.8 umol per liter ) Diabetes Uncontrolled hypertension ( systolic blood pressure &gt; 190 mm Hg diastolic blood pressure &gt; 100 mm Hg ) Uncontrolled hypothyroidism ( thyroidstimulating hormone level 1.5 time upper limit normal range ) Recent history alcohol drug abuse another medical condition might compromise safety successful completion study Exclude patient inflammatory condition severe arthritis , lupus , inflammatory bowel disease , patient take immunosuppressant agent cyclosporine , tacrolimus , azathioprine , longterm oral glucocorticoid Pregnant woman exclude participation study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>